Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1992021348) PHARMACEUTICAL FORMULATIONS OF A BENZODIAZEPINE
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1992/021348 International Application No.: PCT/GB1992/000950
Publication Date: 10.12.1992 International Filing Date: 26.05.1992
Chapter 2 Demand Filed: 17.12.1992
IPC:
A61K 9/48 (2006.01) ,A61K 31/55 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
48
Preparations in capsules, e.g. of gelatin, of chocolate
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
Applicants:
MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road Hoddesdon Hertfordshire EN11 9BU, GB (AllExceptUS)
LIEVENS, Hildegard, Simone, Richard [BE/GB]; GB (UsOnly)
Inventors:
LIEVENS, Hildegard, Simone, Richard; GB
Agent:
BARRETT-MAJOR, Julie, Diane; Merck & Co., Inc. European Patent Department Terlings Park, Eastwick Road Harlow Essex CM20 2QR, GB
Priority Data:
9111858.803.06.1991GB
9204774.505.03.1992GB
Title (EN) PHARMACEUTICAL FORMULATIONS OF A BENZODIAZEPINE
(FR) COMPOSITIONS PHARMACEUTIQUES CONTENANT UNE BENZODIAZEPINE
Abstract:
(EN) Pharmaceutical formulations comprising 3R(+)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)-urea and a pharmaceutically acceptable carrier, characterised in that the carrier comprises a pharmaceutically acceptable oil selected from esterification or polyether products of glycerides with vegetable oil fatty acids of chain length C8-C10 and a pharmaceutically acceptable surfactant selected from oleate and laurate esters of a polyalcohol copolymerised with ethylene oxide are disclosed. They optionally also contain a plasticiser and/or water and/or $g(a)-D-tocopherol. Preferably, the formulations are prepared by known methods and are filled into hard or soft gelatin capsules. The formulations are useful for the treatment or prevention of medical conditions in which an excess of CCK is implicated such as pain, panic or anxiety.
(FR) On décrit des compositions pharmaceutiques comprenant 3R(+)-N-(2,3-dihydro-1-méthyl-2-oxo-5-phényl-1H-1,4-benzodiazépine-3-yl)-N'-(3-méthylphényl)-urée, et un véhicule pharmaceutiquement acceptable, qui se caractérisent en ce que le véhicule se compose d'une huile pharmaceutiquement acceptable choisie à partir des produits d'estérification ou de polyéther de glycérides, ainsi que des acides gras d'huiles végétales dont la longueur de chaîne est de C8 à C10, et un tensioactif pharmaceutiquement acceptable choisi entre les esters d'oléate et de laurate d'un alcool polyvalent copolymérisé avec de l'oxyde d'éthylène. Les compositions contiennent aussi éventuellement un plastifiant et/ou de l'eau et/ou de l'$g(a)-D-tocophérol. De préférence, les compositions sont préparées selon des procédés connus et des capsules de gélatine dures ou souples en sont remplies. Elles peuvent être utilisées pour le traitement ou la prévention d'états pathologiques dus à un excédent de cholécystokinine, tels que la douleur, la peur panique et l'anxiété.
Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)